Immuno Oncology Insights
Latest Publications

TOTAL DOCUMENTS

36
(FIVE YEARS 26)

H-INDEX

0
(FIVE YEARS 0)

Published By Bioinsights Publishing, Ltd.

2634-5099, 2634-5099
Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Microphysiological systems for immuno-oncology: opportunities and challenges

2021 ◽  
Vol 2 (4) ◽  
pp. 203-206
Author(s):  
Lucie A Low
Keyword(s):  
Microphysiological Systems

Recent evolution in the bispecific antibody and engineered cytokine fields

2021 ◽  
Vol 2 (4) ◽  
pp. 195-201
Author(s):  
Raphael Clynes
Keyword(s):  
Bispecific Antibody

Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

2021 ◽  
Vol 2 (4) ◽  
pp. 171-185
Author(s):  
Michael Pawlak ◽  
Markus Templin ◽  
Christian Schmees
Keyword(s):  
Protein Profiling ◽  
Precision Oncology ◽  
Cell Models ◽  
Highly Sensitive

Enhancing preclinical predictivity: what is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

2021 ◽  
Vol 2 (4) ◽  
pp. 225-227
Author(s):  
Christian Schmees

Translational R&D insights for the allogeneic CAR T cell therapy field and beyond

2021 ◽  
Vol 2 (4) ◽  
pp. 187-193
Author(s):  
Barbra Sasu
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Therapy Field

Enhancing preclinical predictivity in I-O: what is going wrong between preclinical in vitro/in vivo and clinical settings?

2021 ◽  
Vol 2 (4) ◽  
pp. 209-224
Author(s):  
Peter Ellmark ◽  
David Gilham ◽  
Martin Steegmaier ◽  
Mihriban Tuna ◽  
Markus Zettl
Keyword(s):  
Clinical Settings

Hunting for better biomarkers of response: where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?

2021 ◽  
Vol 2 (3) ◽  
pp. 133-102
Author(s):  
Dr Adil Daud ◽  
Steven Fling ◽  
John Rossi ◽  
Dr Majid Ghoddusi
Keyword(s):  
Real Progress ◽  
Made In

Leveraging the advantages of liquid biopsy for predictive and prognostic biomarkers in R&D

2021 ◽  
Vol 2 (3) ◽  
pp. 147-149
Author(s):  
Chamindie Punyadeera
Keyword(s):  
Liquid Biopsy ◽  
Prognostic Biomarkers

Reflecting on Merck’s I-O biomarker development journey

2021 ◽  
Vol 2 (3) ◽  
pp. 115-121
Author(s):  
Eric H Rubin, MD Eric H Rubin, MD
Load More ...
Sign in / Sign up

Export Citation Format

Share Document